Xcopri and Keppra are both anti-seizure medications used to treat epilepsy, but they belong to different drug classes and have distinct characteristics.
How do Xcopri and Keppra work differently?
Xcopri (cenobamate) is a calcium channel blocker that works by selectively binding to voltage-gated sodium channels, reducing their ability to recover from inactivation. This helps to stabilize electrical activity in the brain. Keppra (levetiracetam), on the other hand, is a synaptic vesicle protein 2A (SV2A) binder, which is thought to modulate neurotransmitter release by binding to SV2A proteins in the brain [1].
What types of seizures can Xcopri and Keppra treat?
Xcopri is approved for the adjunctive treatment of partial-onset seizures in patients 12 years of age and older [2]. Keppra is also used for the adjunctive treatment of partial-onset seizures, myoclonic seizures in patients with epilepsy, and primary generalized tonic-clonic seizures in patients with epilepsy [1].
What are the potential side effects of Xcopri and Keppra?
Common side effects for Xcopri include somnolence, dizziness, headache, nausea, and upper respiratory tract infection [2]. Keppra's common side effects can include somnolence, asthenia, dizziness, and behavioral abnormalities [1]. A significant concern with Xcopri is the risk of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hypersensitivity, which requires gradual dose titration and patient monitoring [2].
When does the patent for Keppra expire?
The patents for Keppra have expired, making generic versions available. This allows for lower-cost alternatives for patients.
What are the commercial considerations for Xcopri and Keppra?
As Keppra is an older, off-patent medication, it is available in generic forms, generally making it more affordable. Xcopri is a newer, branded medication, and its pricing reflects its patent protection.
What is the clinical data supporting Xcopri and Keppra?
Clinical trials for Xcopri demonstrated a reduction in seizure frequency for patients with partial-onset seizures when used as an add-on therapy [2]. Keppra has also undergone extensive clinical trials demonstrating its efficacy in various seizure types [1].
What are the patient concerns regarding these medications?
Patients often consider side effect profiles, medication cost, and the convenience of dosing when choosing between anti-seizure medications. For Xcopri, patients and healthcare providers must be aware of the risks associated with DRESS syndrome and hypersensitivity [2].
Sources:
1. https://www.drugpatentwatch.com/drug/keppra
2. https://www.drugpatentwatch.com/drug/xcopri